FDA wants more study of diabetes drug heart risk
WASHINGTON (Reuters) - Drug companies should more thoroughly study the potential heart risks of new diabetes medicines, U.S. health officials said on Wednesday.
The Food and Drug Administration, in new guidelines, outlined steps companies should take “to ensure that a new therapy does not increase cardiovascular risk to an unacceptable extent.”
(Reporting by Lisa Richwine; Editing by Lisa Von Ahn)
--------------------------------------------------------------------------------------------Related Posts:
NEW YORK (Reuters) - The rise of serious heart risks in drugs that treat chronic conditions has become one of the U.S. Food and Drug Administration’s top worries and is changing how the agency weighs new medicines, a top FDA official said on Tuesday. The agency is thinking about how to weigh such possible side effects
Full Post: Drugs’ heart risk is FDA’s biggest worry: official
--------------------------------------------------------------------------------------------
WASHINGTON (Reuters) - U.S. regulators are asking drugmakers to submit more details about their supply chains under a pilot program announced on Wednesday to help protect patients from fake or tainted medicines from overseas. Companies that voluntarily provide the information can get the products through U.S. border entry points more quickly, Food and Drug Administration officials
Full Post: U.S. seeks details of supply chains for foreign drugs
--------------------------------------------------------------------------------------------
WASHINGTON (Reuters) - U.S. regulators issued guidelines on Monday that make it easier for drug companies and medical device makers to advise doctors about unapproved uses of their products. The Food and Drug Administration finalized a proposal issued in February 2008 that lets companies distribute medical journal articles describing unapproved uses. By law, manufacturers are prohibited from
Full Post: FDA lets drugmakers advise doctors on unapproved uses
--------------------------------------------------------------------------------------------
WASHINGTON (Reuters) - Makers of epilepsy drugs must add a warning that the medicines carry a risk of suicidal thoughts or actions, U.S. health officials said on Tuesday. “The risk of suicidal thoughts or behavior was generally consistent among the eleven drugs analyzed and was observed in patients who were treated for epilepsy, psychiatric disorders, and
Full Post: FDA orders suicidal action warning on epilepsy drugs
--------------------------------------------------------------------------------------------
By Lisa Richwine WASHINGTON (Reuters) - U.S. regulators should make sure high-risk medical devices undergo the agency’s toughest review process before they are allowed on the market, a congressional watchdog report said on Thursday. The Food and Drug Administration oversees devices ranging from simple bandages and tongue depressors to the most complex such as pacemakers and heart-valve
Full Post: GAO urges tougher review of some medical devices